Sign up
Pharma Capital

Summit Therapeutics says PhaseOut DMD clinical trial did not meet primary endpoint

The AIM-listed pharmaceuticals group said that because of the outcome, it is discontinuing its development of ezutromid and as a result, will be implementing cost reduction measures
Clinical trial
Summit said it was exploring whether any information gathered could support other research

Summit Therapeutics PLC (LON:SUMM; NASDAQ:SMMT) said that its PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne muscular dystrophy (DMD).

The AIM-listed pharmaceuticals group said that because of the outcome, it is discontinuing its development of ezutromid and as a result, will be implementing cost reduction measures.

READ: Summit Therapeutics unveils second series of compounds which could kill gonorrhoea bacteria

Summit added that it would now focus its operations on the development of its pipeline of new mechanism antibiotics, with its lead product candidate, ridinilazole, expected to enter Phase 3 clinical trials for the treatment of C. difficile infection in the first quarter of 2019.

The company also said it would investigate whether information gathered as part of PhaseOut DMD phase 2 clinical trial could be made available to support other research activities in DMD for the benefit of the DMD community.

View full SUMM profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.